Arcus Biosciences (RCUS) EBT Margin (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly EBT Margin came in at 752.94% in Q1 2026, down 35294.0% year-on-year from N/an in Q1 2025, and down 134.41% quarter-over-quarter from 321.21% in Q4 2025.
Arcus Biosciences (RCUS) EBT Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBT Margin history runs 10 years deep, the most recent figure standing at 752.94% for Q1 2026.
- On a quarterly basis, EBT Margin fell 35294.0% year-over-year to 752.94% in Q1 2026; TTM through Mar 2026 was 156.36%, a 12024.0% increase from a year earlier, with the FY2025 full-year figure at 142.91%, down 3361.0% from the prior year.
- EBT Margin retreated to 752.94% in Q1 2026 per RCUS's latest filing, from 321.21% in the prior quarter.
- Across five years, EBT Margin topped out at 2.76% in Q1 2024 and bottomed at 752.94% in Q1 2026.
- The 5-year median for EBT Margin is 283.59% (2023), against an average of 322.04%.
- Across the five-year window, EBT Margin surged 62720 bps in 2022 and tumbled 39724 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 197.06% in 2022, then plunged by 190 bps to 571.43% in 2023, then jumped by 37 bps to 357.69% in 2024, then climbed by 10 bps to 321.21% in 2025, then tumbled by 134 bps to 752.94% in 2026.
- Per Business Quant, the three latest RCUS EBT Margin figures stand at 752.94% (Q1 2026), 321.21% (Q4 2025), and 519.23% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcus Biosciences | 3.73 Bn | 2.90 Bn | - | -752.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -752.94% |
| Dec 31, 2025 | -321.21% |
| Sep 30, 2025 | -519.23% |
| Mar 31, 2025 | -400.00% |
| Dec 31, 2024 | -357.69% |
| Sep 30, 2024 | -191.67% |
| Jun 30, 2024 | -238.46% |
| Mar 31, 2024 | -2.76% |
| Dec 31, 2023 | -571.43% |
| Sep 30, 2023 | -215.63% |
| Jun 30, 2023 | -255.17% |
| Mar 31, 2023 | -312.00% |
| Dec 31, 2022 | -197.06% |
| Sep 30, 2022 | -196.97% |
| Jun 30, 2022 | -248.15% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | -824.17% |
| Jun 30, 2021 | -802.98% |
| Mar 31, 2021 | -767.29% |